Latest Financial Results
Q3 2022
Quarterly Results
Ended Jul 31, 2022
Stock Information
Symbol
ANIXPrice
Change
Volume
52 week Low/High
Day Low/High
Company Overview
Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function. The company's vaccine portfolio includes a vaccine to prevent breast cancer, and specifically triple negative breast cancer (TNBC), the most deadly form of the disease, and a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against specific proteins that have been found to be expressed in certain forms of cancer. Anixa continually examines emerging technologies in complementary fields for further development and commercialization.
Latest News & Events
Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Presented at the Rivkin Center & American Association of Cancer Research (AACR) 14th Biennial Ovarian Cancer Research Symposium
Read More...Anixa Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Read More...Anixa Biosciences Announces Treatment of First Patient in its Ovarian Cancer CAR-T Clinical Trial
Read More...